Kronos Bio

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Kronos sheds staff despite positive data for cancer drug

A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.

News

NHS staff 'feel unprepared for digital transformation'

A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks